RxDoctor Payments Data

James Steier, MD

Rheumatology · Provo, UTNPI 1255402798

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Amgen at 33.6% of the total. 2025 is the largest year on record at $664, more than ten times the $14 reported in 2019.

$2,055in general payments, 2019–2025

Across 100 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$691
  • AbbVie$311
  • AstraZeneca$251
  • Pfizer$217
  • Novartis$102
  • GSK$91
  • plus $392 from 10 others

What the payments were for

  • Food & beverage$1,94995%
  • Education$1055%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,055 in reported general payments places this provider in the 65th percentile of 52 rheumatology providers in Utah.

See all rheumatology providers in Utah

Medicare billing

Part B allowed, 2024
$157,234
Medicare patients
173
Services billed
6,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib58$412,191
Enbrel SureclickEtanercept23$196,232
Humira(Cf) PenAdalimumab13$83,914
Xeljanz XrTofacitinib Citrate13$73,319
OrenciaAbatacept11$65,682
Amjevita(Cf) AutoinjectorAdalimumab-Atto12$36,111
Leflunomide13$2,160
Hydroxychloroquine Sulfate64$1,696
Prednisone145$1,624
Febuxostat22$1,424
MethotrexateMethotrexate Sodium44$1,390
Celecoxib28$1,104
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$964
Gabapentin56$940
Diclofenac Sodium17$765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$311$412,19158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 52 rheumatology providers in Utah.

Other rheumatology in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →